论文部分内容阅读
对24例临床确诊为恶性肿瘤的患者进行血清可溶性白细胞介素-2受体（SIL-2R）检测。结果表明：（1）恶性肿瘤患者血清中SIL-2R水平与正常对照组有显著性差异。（2）恶性肿瘤病人经放、化治疗后，SIL-2R水平明显下降，治疗前后SIL-2R对比有显著性差异。上述结果提示SIL-2L水平测定可作为恶性肿瘤病人放、化疗后，机体免疫功能状态的指标之一。
Serum soluble interleukin-2 receptor (SIL-2R) was detected in 24 patients with clinically diagnosed malignancy. The results showed that: (1) Serum levels of SIL-2R in patients with malignant tumors were significantly different from those in normal controls. (2) SIL-2R levels were significantly decreased in patients with malignant tumors after radiotherapy and chemotherapy. There was a significant difference in SIL-2R levels before and after treatment. The above results suggest that SIL-2L level can be used as one of the indicators of immune function status of patients with malignant tumors after radiotherapy and chemotherapy.